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Abstract
The objective of this study was to address the evolution of human immunodeﬁciency virus type 1 (HIV-1) mutations resistant to the
integrase inhibitor raltegravir after drug interruption. Thirteen HIV-1 infected patients undergoing virological failure due to the selection
of raltegravir-resistant variants, who had interrupted raltegravir treatment, were enrolled. For all patients, the virological failure was
associated with the selection of variants, with mutations conferring resistance to all of the drugs present in their regimens. Patients
were prospectively monitored at baseline (raltegravir interruption) and every 4–24 weeks for clinical, virological and immunological
parameters, including HIV-1 viraemia, CD4+ T-cell counts, and sequence analysis of the HIV-1 integrase sequence. Reversion to the
wild-type HIV-1 integrase sequence genotype was observed between 4 and 36 weeks after raltegravir withdrawal in eight out of the 13
patients. Reversion was not observed in three patients. In two patients, reversion was partial at week 24 from raltegravir interruption.
These results highlight that in eight out of 13 patients under treatment with raltegravir and experiencing a virological failure, HIV-1
variants harbouring mutations associated with raltegravir resistance become undetectable after drug interruption within a few weeks
(in some cases, very rapidly). This occurs under different therapy regimens and in patients receiving 3TC mono-therapy. In the
other patients, complete reversion of the integrase sequence is not observed, and either primary or secondary resistance mutations are
ﬁxed in the replication competent viral population in vivo also for long time, suggesting that other factors may inﬂuence this dynamic
process.
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Introduction
Raltegravir, the prototype of a new class of anti-retroviral
compounds (integrase inhibitors; INI), has been demonstrated
to be an effective drug in the treatment of either naı¨ve or
experienced human immunodeﬁciency virus type 1 (HIV-1)
infected subjects [1–4]. As for other classes of anti-retroviral
drugs, the selection of variants carrying drug-resistance-associ-
ated mutations in the HIV-1 integrase sequence has been
described in patients not responding to raltegravir including
regimens [1]. Moreover, in subjects maintaining raltegravir in
their regimen despite the selection of resistance mutations, a
detectable increase in HIV-1 resistance levels to raltegravir
driven by the continuous evolution of the viral integrase
sequence has been documented [5–7]. Finally, comparative
analyses of the geno-phenotypic features of resistant variants
selected during raltegravir treatment in vivo have indicated that
the replication capacity (RC) of resistant clones is compro-
mised in INI-resistant HIV-1 variants [8–12].
In the past two decades, studies of different classes of
anti-retroviral compounds have demonstrated that viral
reversion from highly resistant to fully susceptible wild-type
viral variants is generally observed within a variable time in
cell-free plasma virus after interruption of the compounds
[13,14]. It is presently believed that the lower relative ﬁtness
of resistant variants allows the reversion to wild-type archi-
val provirus sequences in the absence of drug-selection pres-
sure. Of note, secondary (or compensatory) and rarely
primary mutations (such as the 103N in the reverse
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transcriptase HIV-1 sequence) not associated with reduction
of viral RC [15] are maintained in some cases after drug
interruption, thus remaining as genotypic scars in the repli-
cating virus. These footprints of previous failing regimens
may be useful from a diagnostic point of view in either naı¨ve
or treatment-exposed patients, facilitating the determination
of the most reliable historical GSS score [16]. Recently, sev-
eral studies have evaluated the genotypic and phenotypic pat-
terns of raltegravir-resistant variants selected in vivo,
elucidating the role of drug resistance and RC in patients not
responding to regimens including raltegravir [8–12]. How-
ever, data on the genotypic monitoring of the evolution of
raltegravir-associated resistance mutations after drug inter-
ruption are still limited. Due to the importance of increasing
the therapeutic options for HIV-1 infected subjects, these
results could be central to the understanding of the biology
of raltegravir-resistant variants and to the diagnostic manage-
ment of patients treated with raltegravir.
Patients and Methods
This research was conducted in accordance with the Decla-
ration of Helsinki and national and institutional standards and
was approved by the San Raffaele Ethical Committee.
Genotypic analyses, virological and immunological
evaluation
Thirteen patients (age, 49 ± 11 years; 11 male, 2 female),
who underwent virological failure due to the selection of
HIV-1 (subtype B) resistant variants, and who had inter-
rupted raltegravir treatment, were enrolled in the present
study. All patients had a long history of treatment (on aver-
age 16 years of documented antiretroviral therapy), with an
average duration of HIV-1 infection of 19 years.
Patients were prospectively monitored at baseline (time of
raltegravir interruption) and every 4–32 weeks for clinical,
virological and immunological parameters, including HIV-1
viraemia (Versant HIV-qRNA 3.0 Assay; Siemens Healthcare
Diagnostics, Deerﬁeld, IL, USA), and CD4+ T-cell counts
(Fig. 1 and Table 1).
Genotypic analyses of the reverse transcriptase and prote-
ase sequences and of the env gene to evaluate the presence of
mutations associated with drug resistance or changes in viral
tropism, were also performed at the beginning of
the raltegravir-including regimen, at virological rebound and
during maintenance of raltegravir despite failure [5,9]. After
raltegravir interruption (the baseline point for this study) pol
and env genotypic analyses were performed at multiple time--
points (every 4–40 weeks) (for Methods see Ref. [5 and 9]).
Ampliﬁcation of HIV-1 integrase sequence
Viral RNA was puriﬁed using the QIAmp viral RNA mini kit
(Qiagen, Valencia, CA, USA). Only one sample at each time
point was processed, and clinical samples and all ampliﬁcation
steps were carried out using a limiting dilution strategy to
minimize artiﬁcial recombination events. The integrase region
spanning codons 1–288 was targeted, using the following
nested-RT-PCR using primers Int1F, 5¢- CAT GGG TAC
CAG CAC ACA CAA AGG-3¢ and Int1R, 5¢-CCA TGT
TCT AAT CCT CAT CCT GTC -3¢ for the ﬁrst PCR round,
while primers Int2F 5¢-GGA ATT GGA GGA AAT GAA
CAA GTA GAT -3¢ and Int2R 5¢GCC ACA CAA TCA TCA
CCT GCC ATC-3¢ were used in the second PCR round.
The ﬁrst nested-RT-PCR reaction was performed in 50 lL
using the SuperScriptTM III Platinum High-Fidelity One-Step
qRT-PCR System (Invitrogen, Carlsbad, CA, USA) with the
following thermal proﬁle: 30 min at 50C and 10 min at
95C for 1 cycle, 1 min at 95C, 1 min at 52C and 1 min
and 10 s at 72C for 50 cycles followed by 10 min at 72C.
The nested PCR reaction was performed in 100 lL using the
PCR SuperMix High Fidelity (Invitrogen) with the same ther-
mal proﬁle. Direct sequencing was performed using an ABI
PRISM 3100 Genetic Analyzer (Applied Biosystem, Foster
City, CA, USA). Resistance to raltegravir was evaluated
according to the Stanford database report and published ex
vivo phenotypic data [8–12]. As evaluated by serial dilutions
of TA-cloned (Invitrogen) reference (NL4-3 derived) ampli-
cones spiked in plasma samples obtained from HIV-1-nega-
tive patients, this assay was demonstrated to have an
analytical sensitivity of about 240 copies with subtype B vari-
ants [9,17]. The electropherogram was analysed manually by
a trained virologist to guarantee that resistant variants pres-
ent in a proportion higher than 5–10% in the viral population
could be identiﬁed.
Results and Discussion
In the present study, 13 HIV-1 infected patients not respond-
ing to a raltegravir-containing regimen were enrolled. Viro-
logical and immunological parameters as well as the
therapeutic regimens are shown in Fig. 1 and Table 1. For all
patients, virological failure was associated with selection of
variants with mutations conferring resistance to all of the
drugs present in their regimens (data not shown). In particu-
lar, failure of response to raltegravir was associated with the
selection of variants displaying different combinations of
primary and secondary mutations after 4–56 weeks
(Table 1). In many of them, especially in those where failure
was associated with signature mutations other than the
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FIG. 1. Virological and immunological parameters of the patients described in the study and patients’ therapies. AZT, zidovudine; FTC, emtricita-
bine; TdF, tenofovir; RAL, raltegravir; ETR, etravirine; 3TC, lamivudine; DRV, darunavir; ENF, enfuvirtide; MVC, maraviroc; ABC, abacavir; f-APV,
fosamprenavir; LPV/r, lopinavir/ritonavir; DRV/r, darunavir/ritonavir; TPVr, tipranavir/ritonavir.
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TABLE 1. Mutations associated with failure to respond to therapeutic raltegravir including regimens, and immunological and
virological parameters. Patients’ therapies and resistance mutations to raltegravir at each time-point
Patient
Weeks
after RAL
start
Weeks
after RAL
interruption
RAL-associated
resistance mutations Therapy
CD4+ T
cells/mm3
Copies HIV
RNA/mL
P1 0 7 2 35 613
4 T206S,V72I RAL + ETV + TDF + FTC 8 1 49 893
8 T206S,V72I RAL + ETV + TDF + FTC 24 47 291
16 T206S,V72I RAL + ETV + TDF + FTC 130 34 832
24 Y143R V165I,T206S RAL + ETV + TDF + FTC 13 1 00 000
36 Y143H/C/R, V165I, V201V/I, T206S RAL + ETV + TDF + FTC 62 91 579
52 Y143YH/C/R, V165I, V201V/I, T206S 19 84 372
56 4 V165I, V201V/I, T206S 37 2 68 771
P2 0 TDF + FTC 224 74
56 G140G/S, Q148R RAL + ENF + TDF + FTC 206 1574
60 G140G/S, Q148R RAL + ENF + TDF + FTC 213 2152
64 4 WT TDF + FTC + DRV/r + ETV 223 7593
P3 0 92 49
4 E138K, Y143K, Q148R RAL + MVC + TDF + FTC 159 30 035
8 G140S,Y143R RAL + MVC + TDF + FTC 179 51 439
16 T97A,E138A,Y143K RAL + MVC + TDF + FTC 106 84 658
20 G140S,Q148H RAL + DRV/r + MVC + TDF + FTC 135 32 935
28 G140S,Q148H RAL + DRV/r + MVC + TDF + FTC 179 25 157
84 E138A,G140S,Y143H,Q148H,K156N RAL + DRV/r + MVC + TDF + FTC 96 1 02 180
96 12 E138A,G140S,Y143H,Q148H,K156N DRV/r + TDF + FTC 78 94 080
P4 0 TDF + FTC + ENF + LPV/r 101 8785
24 G140S,Q148H RAL + ATV + ENF + MVC 22 75 391
48 G140S,Q148H RAL + ATV + ENF + MVC 38 2 15 980
72 12 T125A,G140S,Q148H/Q DRV/r + TDF + FTC 10 90 170
96 36 WT,T125A TDF + FTC + DRV/ + ENF 4 2 75 751
P5 0 RAL + MVC + DRV/r 142 82 000
4 G140S, Q148R, G163R RAL + MVC + DRV/r 136 72 072
44 G140S,Q148R,G163R RAL + MVC + DRV/r 323 1 55 000
68 G140S, Q148H, G163R RAL + DRV/r 198 2 34 901
104 12 WT ENF + DRV/r + ETV + MVC 48 1 09 500
P6 0 70 3 93 022
20 T97A, Y143C RAL + TDF + FTC + ENF 68 38 883
28 T97A, Y143C RAL + TDF + FTC + ENF 85 735
32 L74M, T97A, Y143C/G RAL + TDF + FTC + ENF 96 6 39 595
36 T97A, Y143C RAL + TDF + FTC + DRV/r + MVC + ENF 209 642
52 T97A, Y143R RAL + TDF + FTC + DRV/r + MVC + ENF 288 240
64 L74M, T97A, E138A,Y143C RAL + TDF + FTC + DRV/r + MVC + ENF 281 836
76 L74M, T97A, E138A,Y143C RAL + TDF + FTC + DRV/r + MVC + ENF 213 3116
88 L74M, T97A, E138A,Y143C RAL + TDF + FTC + DRV/r + MVC + ENF 306 32 190
92 12 T97A, Y143C 3TC 180 2 77 300
104 24 WT 3TC 62 82 920
P7 0 595 14 500
16 G140S,Q148R RAL + FTC + MVC + TDF 451 14 070
20 4 WT 3TC 494 13 380
P8 0 225 9513
24 Y143R RAL + ETV + 3TC 359 6497
32 T97A, Y143R RAL + ETV + 3TC 376 6527
44 T97A, Y143R RAL + ETV + 3TC 418 7728
84 4 L74M, T97A, Y143R TDF + FTC + DRV/r 270 986
92 12 WT TDF + FTC + DRV/r 272 472
P9 0 214 267
24 T125A,E138K,G140S, Q148H RAL + ATV + TDF + FTC 364 22 281
76 52 G140S, Q148H ETV + DRV/r + MVC 494 49
112 88 T125A,G140S,Q148H ETV + DRV/r + MVC 371 49
120 96 T125A,G140S,Q148H ETV + DRV/r + MVC 328 2593
P10 0 194 17 087
44 G140S, Q148H RAL + DRV/r + ETV + 3TC 416 7871
80 G140S,Q148H,G163E RAL + DRV/r + ETV + 3TC 372 4693
84 4 G140S,Q148H,G163E TDF + FTC + DRV/r 302 2213
92 10 G140S,Q148H,G163E TDF + FTC + DRV/r 370 5511
P11 0 V201I 551 209
8 V201I,Y143S RAL + ABC + 3TC + fAPV 620 8484
16 V125A,V151I,N155H,V201I RAL + ABC + 3TC + fAPV 634 26 448
32 T97A,V125A,V151I,N155H,V201I RAL + ABC + 3TC + fAPV 597 22 129
64 32 T97A,G143S ETV + 3TC + DRV/r 580 569
96 64 G163Q ETV + 3TC + DRV/r 970 57
112 80 G163Q ETV + 3TC + DRV/r 1012 45
P12 0 RAL + TPV/r + 3TC 260 7220
24 L74M, T97AT, Y143R, V165I RAL + TPV/r + 3TC 92 80 700
52 24 L74M, Y143R, V165I DRV/r + 3TC 286 203
P13 0 RAL + TDF + FTC + LPV/r + AZT 250 48 616
36 G140S,Q148H RAL + ETV + DRV/r 335 1 73 753
112 40 G140S,Q148H TDF + FTC + DRV/r 311 43 970
AZT, zidovudine; FTC, emtricitabine; TdF, tenofovir; RAL, raltegravir; ETR, etravirine; 3TC, lamivudine; ENF, enfuvirtide; MVC, maraviroc; ABC, abacavir; f-APV, fosamprena-
vir; LPV/r, lopinavir/ritonavir; DRV/r, darunavir/ritonavir; TPVr, tipranavir/ritonavir.
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G140S + Q148H combination, a dynamic evolution of the
viral population was documented, as previously described
[5,9]. Despite the low number of patients and the variability
in the sampling times as well as in the length of the follow-
ups between patients, several important observations could
be made on the evolution of the viral population after ralte-
gravir interruption.
After failure of the raltegravir-including regimen, one
patient (#1) underwent antiretroviral therapy (ART) inter-
ruption. Due to the absence of other therapeutic options
two patients (patients #6 and #7) were maintained under
3TC monotherapy [18], while all the others switched to the
best possible raltegravir-sparing regimen based on the results
of genotype, viral tropism and clinical history.
In eight out of the 13 patients (Table 1, patients # 1, 2, 4,
5, 6, 7, 8 and 11), reversion to the wild-type HIV-1 integrase
sequence genotype was observed after 4–36 weeks from ral-
tegravir withdrawal. In contrast, reversion was not observed
in four patients (patients # 3, 9, 10 and 13). In one patient
(patient # 12) reversion was partial at week 24 from ralte-
gravir interruption, with the Y143R mutation still present at
the genotypic evaluation. In detail, both primary and second-
ary mutations acquired at drug failure disappeared if not
present at baseline in all subjects, with the exceptions of
patient # 1 (V165I not present at baseline), patient # 4
(T125A) and patient # 11 (G163Q). While the ﬁrst two vari-
ants are more frequently found as polymorphisms, mutations
in position 163 are rare in subtype B viruses [19]. Although
we can hypothesize that many secondary mutations under-
went carryover negative selection driven by the reduction of
viral ﬁtness conferred by primary mutations, we cannot
exclude that some of them have per se a direct impact on
integrase efﬁciency and viral RC, and are very infrequently
found in the circulating viruses worldwide [19]. Additionally,
a progressive substitution of the resistant variants by the
wild-type viruses occurred in multiple steps in two patients
(patients #6 and #11). Moreover, amino acidic reversion was
associated with the reappearance of pre-raltegravir nucleo-
tide sequences and the speed of reversion of each resis-
tance-associated codon combination was not proportional to
the number of nucleotide changes needed to revert to the
wild-type integrase sequence.
We must underline, however, that the analysis of integr-
ase region was performed by direct sequencing, thus we
could describe only major variations in the composition of
the replicating viral population and resistant variants may
have remained undetected if present below 5–10% in the
quasispecies.
The individual differences in time required to revert to a
wild-type genotype may be related to different conditions or
factors. An important factor could be the efﬁcacy of ART.
For patient # 9, the switch to ETV DRV/r and MVC
appeared to be effective and viraemia dropped to low levels
within 8 weeks. This could have inﬂuenced virus evolution,
being the reason for the lack of reversion after 96 weeks of
raltegravir withdrawal. On the contrary, a successful therapy
(although with a slower viral decay) did not give similar
results in the HIV-1 integrase sequence evolution of patient
# 11; in this patient, a progressive, slow and multistep rever-
sion to wild type was observed. Interestingly, the G143S
mutation (+T97A), which has no effect on viral RC, replaced
other variants associated with a lower relative RC (N155H)
[9], before a wild-type variant still containing the G163Q
mutation was selected. A similar observation can be made
for patient # 6, who remained on 3TC monotherapy; in this
patient, the circulating Y143C + T97A + L74M + E138A vari-
ant was rapidly substituted by the Y143C + T97A variant
selected at week 24, and not with the Y143R + T97A com-
bination, previously present and associated with lower RC
[9].
The lack of reversion observed in other patients, including
patients # 3 and # 10, where the resistant variants remained
as the main circulating populations, may be due to the lim-
ited time (12 and 10 weeks, respectively) elapsed between
raltegravir withdrawal and the last available genotype. How-
ever, in some subjects with identical patterns of resistance
mutations, variants carrying resistance mutation became
undetectable very rapidly after raltegravir interruption. As a
further proof of the heterogeneous effect on HIV-1 biology
of resistance-associated mutations, in one patient (patient
#13) genotypic reversion to wild type was not observed
even 40 weeks after raltegravir withdrawal, suggesting that in
this particular patient the G140S + Q148H combination may
not be associated with a reduced viral RC.
Of note, despite the modest viral RC reduction associated
with raltegravir-resistant mutations in vitro [8–12], INI resis-
tant variants became undetectable after raltegravir interrup-
tion in eight out of 13 patients under study, suggesting that
the ﬁtness reduction is sufﬁcient to favour wild-type
sequences in vivo. In this scenario, several reasons may
explain the differences in time necessary to obtain a com-
plete genotypic reversion. Firstly, the inﬂuence on viral RC
associated with raltegravir-resistant mutations may differ
among patients, being modulated by the genetic background
of the circulating integrase sequences. Secondly, the overall
HIV-1 ﬁtness in vivo may also be inﬂuenced by changes of
viral proteins other than the integrase due to multiple resis-
tance mutations, especially in patients with a long history of
antiretroviral treatment, such as those enrolled in this study.
In fact, the complete or partial interruption of the drugs
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present in the raltegravir-including regimen, or alternatively,
the complete switch to a different regimen (associated
with resistance mutations located in distinct viral genes),
may theoretically inﬂuence the composition of the viral
population and the reselection of the variants carrying the
wild-type integrase sequence. However, during the present
study, all the patients that were maintained under a com-
bination of RT and PR inhibitors did not document major
variations in the reverse transcriptase and protease HIV-1
sequences (data not shown). Failure to respond to Maravi-
roc was associated with changes in tropism (data not
shown). In those patients that received the 3TC mono-
therapy and in patient #8, partial reversion was docu-
mented in the protease sequence with loss of mutations
associated with viral RC reduction [20] (in patient # 6,
V32I and I47V; in patient # 7 and #8, I54L).
In conclusion, this study highlights that in patients under
treatment with raltegravir and experiencing virological fail-
ure, circulating HIV-1 variants harbouring mutations associ-
ated with raltegravir resistance may rapidly be substituted by
wild-type viruses after drug interruption. The reversion
occurs within a few weeks (in same cases, very rapidly) and
under different therapy regimens, including patients receiving
3TC monotherapy. This underlines the need for prompt and
frequent genotype monitoring in patients failing to respond
to raltegravir-containing regimens in order to plan future
therapies. In a few patients, however, complete reversion of
the integrase sequence is not observed, and either primary
or secondary resistance mutations are ﬁxed in the main
circulating viral population in vivo also for a long time. Spe-
ciﬁc studies of the relative RC of these variants and analyses
of the overall viral ﬁtness in these HIV-1-infected patients
with a long history of treatment could be useful in fully
clarifying all the aspects of raltegravir resistance.
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